All Stories

  1. Relationship between bone marrow iron load and liver iron concentration in dialysis-associated haemosiderosis
  2. Interest of HIF stabilizers in home dialysis
  3. Cost of Home Dialysis in France
  4. Stage V Chronic Kidney Disease: A plea for Home Dialysis
  5. Financial Barriers to the Optimal Use of Peritoneal Dialysis in France and Europe, as in the United States
  6. Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
  7. Inflammation, Serum Iron, and Risk of Mortality and Cardiovascular Events in Nondialysis CKD Patients
  8. Why and how should we promote home dialysis for patients with end-stage kidney disease during and after the coronavirus 2019 disease pandemic? A French perspective
  9. A dialysis doctor’s memories with COVID-19 disease
  10. Analysis of liver iron concentration in an elderly female undergoing hemodialysis with calcific uremic arteriolopathy does not support the role of iron overload in calciphylaxis: lesson for the clinical nephrologist
  11. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients
  12. Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients
  13. Hepatic iron load differs strikingly between peritoneal dialysis and hemodialysis patients
  14. What do we learn about the “Anemia Module” of the French language Peritoneal Dialysis ? Interest and Results
  15. Confounding factors of hazards of long-acting ESA
  16. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations
  17. Impact des comorbidités sur la stabilité de l’hémoglobine chez des patients insuffisants rénaux chroniques en hémodialyse, traités par CERA en pratique courante : l’étude MIRIADE
  18. Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study
  19. La réalité de la dialyse péritonéale en France : 40 ans après
  20. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?
  21. L’utilisation de génériques en transplantation : vers des solutions rationnelles et sures !
  22. Re: Further Evidence Supporting the Accuracy of Quantitative Magnetic Resonance Imaging for Evaluating Iron Load in Dialysis Patients
  23. Iatrogenic iron overload and its potential consequences in patients on hemodialysis
  24. The changing landscape of iron overload disorders at the beginning of the 21st century
  25. Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis
  26. HFE gene mutations are not risk factors for iron overload in European hemodialysis patients
  27. Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution
  28. Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study
  29. Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients
  30. Intérêt de la dialyse péritonéale dans le traitement de l’insuffisance rénale aiguë de l’adulte : redécouverte d’une modalité complémentaire d’épuration extracorporelle continue
  31. Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
  32. Use of Iron Therapy in Chronic Kidney Disease
  33. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
  34. Utilisation des dérivés injectables du fer au cours de la maladie rénale chronique : intérêts, limites et conseils pour un bon usage
  35. Iatrogenic Iron Overload in Dialysis Patients
  36. Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study
  37. Maximal Standard Dose of Parenteral Iron for Hemodialysis Patients: An MRI-Based Decision Tree Learning Analysis
  38. Actualités sur la prise en charge de l’anémie et de la carence martiale du dialysé
  39. Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-Associated Anemia
  40. Traitement de l’addiction au tabac au cours des maladies rénales chroniques
  41. Hemodialysis
  42. Colloids in Dialytic Refractory Hypotension
  43. Single-Needle Hemodialysis on Native Fistulae
  44. Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI Study
  45. Modulation of oxidative stress and microinflammatory status by colloids in refractory dialytic hypotension
  46. Cinacalcet to prevent parathyrotoxic crises in hypercalcaemic patients awaiting parathyroidectomy
  47. Renal Artery Stenosis Evaluation in Chronic Kidney Disease Patients: Nonenhanced Time-Spatial Labeling Inversion-Pulse Three-dimensional MR Angiography with Regulated Breathing versus DSA
  48. La technique d’hémodialyse transitoire en uniponcture sur fistules natives : intérêts, limites, risques et précautions
  49. Accuracy and limitations of equations for predicting the glomerular filtration rate during follow-up of patients with non-diabetic nephropathies
  50. Left-Ventricular Diastolic Dysfunction as a Risk Factor for Dialytic Hypotension
  51. Improving the Efficiency of Short-Term Single-Needle Hemodialysis
  52. Secretory IgA are elevated in both saliva and serum of patients with various types of primary glomerulonephritis
  53. Quinze pour cent de patients dialysés traités par DPCA/DPA en 2010 : mythe ou réalité ?
  54. Candesartan Cilexetil on Regular Hemodialysis: Inability to Reduce Excessive Thirst, but Good Tolerance and Efficacy in Hypertensive Patients
  55. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency
  56. Les traitements médicamenteux du fibrome utérin
  57. Increased intestinal intra‐epithelial T lymphocytes in primary glomerulonephritis
  58. Sch??nlein-Henoch Purpura in Children and Adults
  59. Vascular Hyperpermeability in Nephrotic Edema
  60. Parvovirus B19 and Schönlein-Henoch Purpura in Adults
  61. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy?
  62. Therapy of IgA Nephropathy
  63. Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation
  64. Role of Lipoprotein-Bound NEFAs in Enhancing the Specific Activity of Plasma CETP in the Nephrotic Syndrome
  65. Drug-induced linear IgA disease: target antigens are heterogeneous
  66. A Cost Analysis of the Prevention of End-stage Renal Disease
  67. Therapy of Idiopathic Membranous Nephropathy
  68. Renal involvement in toxic epidermal necrolysis
  69. Type I membranoproliferative glomerulonephritis and HCV infection
  70. Further identification of human plasma glycoproteins interacting with the galactose-specific lectin Jacalin
  71. Immunomodulation with Low-Dose Immunoglobulins for Moderate IgA Nephropathy and Henoch-Schönlein Purpura
  72. Low Prevalence of Antibodies to Hepatitis C Virus among Adult Patients with Idiopathic Membranoproliferative Type I Glomerulonephritis in France
  73. Prevention of Thrombotic Complications of the Nephrotic Syndrome by the Low-Molecular-Weight Heparin Enoxaparin
  74. Split tolerance in chimeric GVH mice
  75. High-Dose Immunoglobulin Therapy for Severe IgA Nephropathy and Henoch-Schonlein Purpura
  76. Evaluation of Magnetic Resonance Imaging for the Assessment of Renal Vein Thrombosis in the Nephrotic Syndrome
  77. Histone-Reactive IgA Antibodies in Adult IgA Nephropathy and Other Primary Glomerulonephritis
  78. Long-Term Cyclosporin A Therapy for Severe Idiopathic Membranous Nephropathy
  79. Mucosal Immunity in Primary Glomerulonephritis
  80. Proteinuria Selectivity Index -Prognostic Value in Lipoid Nephrosis and Related Diseases
  81. Intravenous IgG for glomerulonephritis and renal function
  82. L'ischémie myocardique silencieuse au cours de l'hémodialyse des insuffisants rénaux chroniques
  83. Heparin Cofactor II in Adult Glomerulopathy and Nephrotic Syndrome
  84. Mucosal Immunity in Primary Glomerulonephritis: II. Study of the Serum IgA Subclass Repertoire to Food and Airborne Antigens
  85. IgA mesangial nephritis, IgA antigliadin antibodies, and coeliac disease
  86. Correspondence
  87. HBV-DNA and Primary Immune Complex Glomerulonephritis
  88. Mucosal Immunity in Adult Primary Glomerulonephritis
  89. Reactivation of Hepatitis B Virus by Corticosteroids in a Case of Idiopathic Nephrotic Syndrome
  90. CYCLOSPORIN IN IDIOPATHIC STEROID-RESISTANT MEMBRANOUS GLOMERULONEPHRITIS
  91. IgA Antigliadin Antibodies as a Possible Marker for IgA Mesangial Glomerulonephritis in Adults with Primary Glomerulonephritis
  92. Idiopathic Nephrotic Syndrome: The Prognosis Is Not Linked to the Total Serum IgE Level
  93. GANCICLOVIR FOR SEVERE CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS
  94. IgA antigliadin antibodies detected by ELISA are not an artifact due to lectin-like activity of gliadin
  95. HIGH LEVELS OF IgA ANTIGLIADIN ANTIBODIES IN PATIENTS WHO HAVE IgA MESANGIAL GLOMERULONEPHRITIS BUT NOT COELIAC DISEASE
  96. Total and free protein S in nephrotic syndrome
  97. Lack of Antireticulin and IgA Antiendomysium Antibodies in Sera of Patients with Primary IgA Nephropathy Associated with Circulating IgA Antibodies to Gliadin
  98. FOOD ALLERGY IN IDIOPATHIC NEPHROTIC SYNDROME
  99. Cutaneous granuloma over a vitallium plate
  100. An Increase in Circulating IgA Antibodies to Gliadin in IgA Mesangial Glomerulonephritis
  101. High Level of Protein C and Protein S in Nephrotic Syndrome
  102. Is Adult Idiopathic Nephrotic Syndrome Food Allergy?
  103. Coexistence of Sézary syndrome and dysmyelopoiesis with an excess of myeloblasts